Open AccessThis article is
- freely available
Novel Combinations for the Treatment of Metastatic Breast Cancer
Weill Cornell Medical College, 425 East 61st Street, 8th Floor, New York, NY 10065, USA
Received: 17 November 2009; in revised form: 29 December 2009 / Accepted: 5 January 2010 / Published: 14 January 2010
Abstract: Anthracyclines and taxanes represent the mainstay of first-line cytotoxic therapy for metastatic breast cancer (MBC), but most patients eventually develop resistance to these agents. Consequently, alternative combinations for MBC therapy are the subject of much ongoing research. Capecitabine and ixabepilone is the only chemotherapy combination specifically approved for MBC after failure of anthracyclines and taxanes. Other options have limited data to support their use in this setting but are commonly used in practice. Future MBC therapies will likely combine alternative chemotherapies and novel biologic agents, and numerous ongoing trials should help to further define the proper use of these regimens.
Keywords: metastatic breast cancer; anthracycline failure; taxane failure; combination therapy; chemotherapy; targeted or biologic therapy; outcomes; survival
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Vahdat, L.T. Novel Combinations for the Treatment of Metastatic Breast Cancer. Cancers 2010, 2, 1-19.
Vahdat LT. Novel Combinations for the Treatment of Metastatic Breast Cancer. Cancers. 2010; 2(1):1-19.
Vahdat, Linda T. 2010. "Novel Combinations for the Treatment of Metastatic Breast Cancer." Cancers 2, no. 1: 1-19.